17 Aug Selective Serotonin Reuptake Inhibitors (SSRIS) and Serotonin–Norepinephrine Reuptake Inhibitors (SNRIS) associated with the risk of Postpartum Haemorrhage
Posted at 11:51h
in
Novartis as directed by the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about the increased incidence of intraocular inflammation (IOI) and related adverse events including retinal vasculitis (RV) and retinal vascular occlusion (RO) associated with (brolucizumab) when administered at 4 weekly intervals beyond the first three doses.
2021 Jun
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
19/06/2021
File Type:
pdf
Category:
Communication To Health Care Professionals